|
1
|
Ritch CR and Cookson MS: Advances in the
management of castration resistant prostate cancer. BMJ.
355:i44052016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
3
|
Harris WP, Mostaghel EA, Nelson PS and
Montgomery B: Androgen deprivation therapy: Progress in
understanding mechanisms of resistance and optimizing androgen
depletion. Nat Clin Pract Urol. 6:76–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pienta KJ and Bradley D: Mechanisms
underlying the development of androgen-independent prostate cancer.
Clin Cancer Res. 12:1665–1671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohler JL, Gregory CW, Ford OH III, Kim D,
Weaver CM, Petrusz P, Wilson EM and French FS: The androgen axis in
recurrent prostate cancer. Clin Cancer Res. 10:440–448. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Agoulnik IU and Weigel NL: Androgen
receptor action in hormone-dependent and recurrent prostate cancer.
J Cell Biochem. 99:362–372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shafi AA, Yen AE and Weigel NL: Androgen
receptors in hormone-dependent and castration-resistant prostate
cancer. Pharmacol Ther. 140:223–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grech G, Baldacchino S, Saliba C, Grixti
MP, Gauci R, Petroni V, Fenech AG and Scerri C: Deregulation of the
protein phosphatase 2A, PP2A in cancer: Complexity and therapeutic
options. Tumour Biol. 37:11691–11700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baldacchino S, Saliba C, Petroni V, Fenech
AG, Borg N and Grech G: Deregulation of the phosphatase, PP2A is a
common event in breast cancer, predicting sensitivity to FTY720.
EPMA J. 5:32014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cristóbal I, Manso R, Rincón R, Caramés C,
Senin C, Borrero A, Martínez-Useros J, Rodriguez M, Zazo S,
Aguilera O, et al: PP2A inhibition is a common event in colorectal
cancer and its restoration using FTY720 shows promising therapeutic
potential. Mol Cancer Ther. 13:938–947. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kauko O, Connor CM, Kulesskiy E, Sangodkar
J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD,
et al: PP2A inhibition is a druggable MEK inhibitor resistance
mechanism in KRAS-mutant lung cancer cells. Sci Transl Med.
10:eaaq10932018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arriazu E, Pippa R and Odero MD: Protein
phosphatase 2A as a therapeutic target in acute myeloid leukemia.
Front Oncol. 6:782016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q,
Huang H, Li J, Tian Z, Jiang G, et al: XIAP overexpression promotes
bladder cancer invasion in vitro and lung metastasis in vivo via
enhancing nucleolin-mediated Rho-GDIβ mRNA stability. Int J Cancer.
142:2040–2055. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mizutani Y, Nakanishi H, Li YN, Matsubara
H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara
K, et al: Overexpression of XIAP expression in renal cell carcinoma
predicts a worse prognosis. Int J Oncol. 30:919–925.
2007.PubMed/NCBI
|
|
15
|
Sung KW, Choi J, Hwang YK, Lee SJ, Kim HJ,
Kim JY, Cho EJ, Yoo KH and Koo HH: Overexpression of X-linked
inhibitor of apoptosis protein (XIAP) is an independent unfavorable
prognostic factor in childhood de novo acute myeloid leukemia. J
Korean Med Sci. 24:605–613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mansouri A, Zhang Q, Ridgway LD, Tian L
and Claret FX: Cisplatin resistance in an ovarian carcinoma is
associated with a defect in programmed cell death control through
XIAP regulation. Oncol Res. 13:399–404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren
S, Liu Z and Zhang L: XIAP is highly expressed in esophageal cancer
and its downregulation by RNAi sensitizes esophageal carcinoma cell
lines to chemotherapeutics. Cancer Biol Ther. 6:973–980. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren K, Gou X, Xiao M, He W and Kang J:
Pim-2 cooperates with downstream factor XIAP to inhibit apoptosis
and intensify malignant grade in prostate cancer. Pathol Oncol Res.
25:341–348. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pagano MA, Tibaldi E, Molino P, Frezzato
F, Trimarco V, Facco M, Zagotto G, Ribaudo G, Leanza L, Peruzzo R,
et al: Mitochondrial apoptosis is induced by Alkoxy
phenyl-1-propanone derivatives through PP2A-mediated
dephosphorylation of Bad and Foxo3A in CLL. Leukemia. 33:1148–1160.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eom T, Muslimov IA, Tsokas P, Berardi V,
Zhong J, Sacktor TC and Tiedge H: Neuronal BC RNAs cooperate with
eIF4B to mediate activity-dependent translational control. J Cell
Biol. 207:237–252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren K, Gou X, Xiao M, Wang M, Liu C, Tang
Z and He W: The over-expression of Pim-2 promote the tumorigenesis
of prostatic carcinoma through phosphorylating eIF4B. Prostate.
73:1462–1469. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang J, Wang J, Chen K, Guo G, Xi R,
Rothman PB, Whitten D, Zhang L, Huang S and Chen JL: eIF4B
phosphorylation by pim kinases plays a critical role in cellular
transformation by Abl oncogenes. Cancer Res. 73:4898–4908. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leonard D, Huang W, Izadmehr S, O'Connor
CM, Wiredja DD, Wang Z, Zaware N, Chen Y, Schlatzer DM, Kiselar J,
et al: Selective PP2A enhancement through biased heterotrimer
stabilization. Cell. 181:688–701.e16. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soerdjbalie-Maikoe V, Pelger RC, Lycklama
à Nijeholt GA, Arndt JW, Zwinderman AH, Bril H, Papapoulos SE and
Hamdy NAT: Bone scintigraphy predicts the risk of spinal cord
compression in hormone-refractory prostate cancer. Eur J Nucl Med
Mol Imaging. 31:958–963. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hwang SS, Chang VT, Alejandro Y,
Mulaparthi S, Cogswell J, Srinivas S and Kasimis B: Study of
hormone refractory prostate cancer: Hospital care and palliative
care resource use at a VA medical center. Cancer Invest.
22:849–857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berruti A, Tucci M, Mosca A, Tarabuzzi R,
Gorzegno G, Terrone C, Vana F, Lamanna G, Tampellini M, Porpiglia
F, et al: Predictive factors for skeletal complications in
hormone-refractory prostate cancer patients with metastatic bone
disease. Br J Cancer. 93:633–638. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inoue T, Segawa T, Kamba T, Yoshimura K,
Nakamura E, Nishiyama H, Ito N, Kamoto T, Habuchi T and Ogawa O:
Prevalence of skeletal complications and their impact on survival
of hormone refractory prostate cancer patients in Japan. Urology.
73:1104–1109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kirby M, Hirst C and Crawford ED:
Characterising the castration-resistant prostate cancer population:
A systematic review. Int J Clin Pract. 65:1180–1192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Antonarakis ES, Tagawa ST, Galletti G,
Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C,
Tsao CK, et al: Randomized, noncomparative, phase II trial of early
switch from docetaxel to cabazitaxel or vice versa, with integrated
biomarker analysis, in men with chemotherapy-naïve, metastatic,
castration-resistant prostate cancer. J Clin Oncol. 35:3181–3188.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
de Bono JS, Logothetis CJ, Molina A,
Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F,
et al: Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ryan CJ, Smith MR, de Bono JS, Molina A,
Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng
S, et al: Abiraterone in metastatic prostate cancer without
previous chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dong L, Zieren RC, Xue W, de Reijke TM and
Pienta KJ: Metastatic prostate cancer remains incurable, why? Asian
J Urol. 6:26–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoang DT, Iczkowski KA, Kilari D, See W
and Nevalainen MT: Androgen receptor-dependent and -independent
mechanisms driving prostate cancer progression: Opportunities for
therapeutic targeting from multiple angles. Oncotarget.
8:3724–3745. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bhardwaj A, Singh S, Srivastava SK, Arora
S, Hyde SJ, Andrews J, Grizzle WE and Singh AP: Restoration of
PPP2CA expression reverses epithelial-to-mesenchymal transition and
suppresses prostate tumour growth and metastasis in an orthotopic
mouse model. Br J Cancer. 110:2000–2010. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhardwaj A, Singh S, Srivastava SK,
Honkanen RE, Reed E and Singh AP: Modulation of protein phosphatase
2A activity alters androgen-independent growth of prostate cancer
cells: Therapeutic implications. Mol Cancer Ther. 10:720–731. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pandey P, Seshacharyulu P, Das S,
Rachagani S, Ponnusamy MP, Yan Y, Johansson SL, Datta K, Lin MF and
Batra SK: Impaired expression of protein phosphatase 2A subunits
enhances metastatic potential of human prostate cancer cells
through activation of AKT pathway. Br J Cancer. 108:2590–2600.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bluemn EG, Spencer ES, Mecham B, Gordon
RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J,
Grandori C, et al: PPP2R2C loss promotes castration-resistance and
is associated with increased prostate cancer-specific mortality.
Mol Cancer Res. 11:568–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cristóbal I, González-Alonso P, Daoud L,
Solano E, Torrejón B, Manso R, Madoz-Gúrpide J, Rojo F and
García-Foncillas J: Activation of the tumor suppressor PP2A emerges
as a potential therapeutic strategy for treating prostate cancer.
Mar Drugs. 13:3276–3286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shah VM, English IA and Sears RC: Select
stabilization of a tumor-suppressive PP2A heterotrimer. Trends
Pharmacol Sci. 41:595–597. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zeng J, Liu W, Fan YZ, He DL and Li L:
PrLZ increases prostate cancer docetaxel resistance by inhibiting
LKB1/AMPK-mediated autophagy. Theranostics. 8:109–123. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Watt LF, Panicker N, Mannan A, Copeland B,
Kahl RGS, Dun MD, Young B, Roselli S and Verrills NM: Functional
importance of PP2A regulatory subunit loss in breast cancer. Breast
Cancer Res Treat. 166:117–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu SY, Wen YC, Ku CC, Yang YC, Chow JM,
Yang SF, Lee WJ and Chien MH: Penfluridol triggers cytoprotective
autophagy and cellular apoptosis through ROS induction and
activation of the PP2A-modulated MAPK pathway in acute myeloid
leukemia with different FLT3 statuses. J Biomed Sci. 26:632019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sangodkar J, Perl A, Tohme R, Kiselar J,
Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor
CM, et al: Activation of tumor suppressor protein PP2A inhibits
KRAS-driven tumor growth. J Clin Invest. 127:2081–2090. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao Z, Kurimchak A, Nikonova AS, Feiser
F, Wasserman JS, Fowle H, Varughese T, Connors M, Johnson K, Makhov
P, et al: PPP2R2A prostate cancer haploinsufficiency is associated
with worse prognosis and a high vulnerability to B55α/PP2A
reconstitution that triggers centrosome destabilization.
Oncogenesis. 8:722019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Remmerie M and Janssens V: PP2A: A
promising biomarker and therapeutic target in endometrial cancer.
Front Oncol. 9:4622019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang J, Okkeri J, Pavic K, Wang Z, Kauko
O, Halonen T, Sarek G, Ojala PM, Rao Z, Xu W and Westermarck J:
Oncoprotein CIP2A is stabilized via interaction with tumor
suppressor PP2A/B56. EMBO Rep. 18:437–450. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
McClinch K, Avelar RA, Callejas D,
Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB,
Schlatzer D, Cooper M, et al: Small-Molecule activators of protein
phosphatase 2A for the treatment of castration-resistant prostate
cancer. Cancer Res. 78:2065–2080. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhong Y, Tian F, Ma H, Wang H, Yang W, Liu
Z and Liao A: FTY720 induces ferroptosis and autophagy via
PP2A/AMPK pathway in multiple myeloma cells. Life Sci.
260:1180772020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Meng G, Wang W, Chai K, Yang S, Li F and
Jiang K: Combination treatment with triptolide and
hydroxycamptothecin synergistically enhances apoptosis in A549 lung
adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt
signaling pathways. Int J Oncol. 46:1007–1017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Galletti G, Leach BI, Lam L and Tagawa ST:
Mechanisms of resistance to systemic therapy in metastatic
castration-resistant prostate cancer. Cancer Treat Rev. 57:16–27.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Amantana A, London CA, Iversen PL and Devi
GR: X-linked inhibitor of apoptosis protein inhibition induces
apoptosis and enhances chemotherapy sensitivity in human prostate
cancer cells. Mol Cancer Ther. 3:699–707. 2004.PubMed/NCBI
|
